Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
556. |
ECCT/25/10/01 | H06_04TP A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years after vaccination in African children. |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI CRC WRP KERICHO |
View |
557. |
ECCT/25/11/01 | COMBO-CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr. Wilson Muraya Site(s) in Kenya 1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county) 2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county) 3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county) |
View |
558. |
ECCT/25/11/02 | DELIVER-02 IGHID 12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya 1. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county) 2. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (MUCRC), ELDORET (Uasin Gishu county) |
View |
559. |
ECCT/25/11/03 | RSV IMPACT TRIAL A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants. |
Principal Investigator(s) 1. Nancy A. Otieno 2. Evans M. Ogoti Site(s) in Kenya Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1) |
View |
560. |
ECCT/25/11/05 | MK-8527-011 Study A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. Dr. Joshua Kimani Site(s) in Kenya 1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county) 2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county) 3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) |
View |